Literature DB >> 34855117

Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort.

Gregory Y H Lip1,2, Giuseppe Boriani3, Vincenzo L Malavasi4, Marco Vitolo4,5,1, Jacopo Colella4, Francesca Montagnolo4, Marta Mantovani4, Marco Proietti1,6,7, Tatjana S Potpara8,9.   

Abstract

The 4S-AF scheme [Stroke risk, Symptom severity, Severity of atrial fibrillation (AF) burden, Substrate severity] was recently proposed to characterize AF patients. In this post hoc analysis we evaluated the agreement between the therapeutic strategy (rate or rhythm control, respectively), as suggested by the 4S-AF scheme, and the actual strategy followed in a patients cohort. Outcomes of interest were as follows: all-cause death, a composite of all-cause death/any thromboembolism/acute coronary syndrome, and a composite of all-cause death, any thrombotic/ischemic event, and major bleeding (net clinical outcome). We enrolled 615 patients: 60.5% male, median age 74 [interquartile range (IQR) 67-80] years; median CHA2DS2VASc 4 and median HAS-BLED 2. The 4S-AF score would have suggested a rhythm-control strategy in 351 (57.1%) patients while a rate control in 264 (42.9%). The strategy adopted was concordant with the 4S-AF suggestions in 342 (55.6%) cases, and non-concordant in 273 (44.4%). After a median follow-up of 941 days (IQR 365-1282), 113 (18.4%) patients died, 158 (25.7%) had an event of the composite endpoint. On adjusted Cox regression analysis, when 4S-AF score suggested rate control, disagreement with that suggestion was not associated with a worse outcome. When 4S-AF indicated rhythm control, disagreement was associated with a higher risk of all-cause death (HR 7.59; 95% CI 1.65-35.01), and of the composite outcome (HR 2.69; 95% CI 1.19-6.06). The 4S-AF scheme is a useful tool to comprehensively evaluate AF patients and aid the decision-making process. Disagreement with the rhythm control suggestion of the 4S-AF scheme was associated with adverse clinical outcomes.
© 2021. Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  4S-AF; Atrial fibrillation; Classification scheme; Mortality; Outcomes; Rhythm Control

Mesh:

Year:  2021        PMID: 34855117     DOI: 10.1007/s11739-021-02890-x

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   5.472


  46 in total

1.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

2.  Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients.

Authors:  Marco Proietti; Alessio Farcomeni; Giulio Francesco Romiti; Arianna Di Rocco; Filippo Placentino; Igor Diemberger; Gregory Yh Lip; Giuseppe Boriani
Journal:  Eur J Prev Cardiol       Date:  2018-12-06       Impact factor: 7.804

3.  The ABC pathway: an integrated approach to improve AF management.

Authors:  Gregory Y H Lip
Journal:  Nat Rev Cardiol       Date:  2017-09-29       Impact factor: 32.419

4.  Anticoagulation to prevent ischaemic stroke in patients with atrial fibrillation: a complex scenario including underdiagnosis, undertreatment, or underdosing of oral anticoagulants.

Authors:  Giuseppe Boriani; Jacopo F Imberti; Marco Vitolo
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2020-04-01

5.  Risk factors and outcomes of new-onset atrial fibrillation in patients hospitalized in an internal medicine ward: a case-control study.

Authors:  Ombretta Para; Lorenzo Caruso; Lorenzo Corbo; Francesca Bacci; Niccolò Pasqui; Filippo Pieralli; Tiziana Ciarambino; Carlo Nozzoli
Journal:  Intern Emerg Med       Date:  2019-07-13       Impact factor: 3.397

6.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Authors:  Gregory Y H Lip; Robby Nieuwlaat; Ron Pisters; Deirdre A Lane; Harry J G M Crijns
Journal:  Chest       Date:  2009-09-17       Impact factor: 9.410

7.  One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study.

Authors:  Roberto Cemin; Furio Colivicchi; Aldo P Maggioni; Giuseppe Boriani; Leonardo De Luca; Andrea Di Lenarda; Giuseppe Di Pasquale; Gianna Fabbri; Donata Lucci; Michele Massimo Gulizia
Journal:  Eur J Intern Med       Date:  2020-01-14       Impact factor: 4.487

8.  Changes in Hepcidin Serum Levels Correlate with Clinical Improvement in Idiopathic Restless Legs Syndrome Patients.

Authors:  Hee-Jin Im; Jee Hyun Kim; Chang-Ho Yun; Dong Wook Kim; Jeeyoung Oh
Journal:  J Clin Med       Date:  2020-12-20       Impact factor: 4.241

Review 9.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

10.  The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification.

Authors:  Gareth J Wynn; Derick M Todd; Matthew Webber; Laura Bonnett; James McShane; Paulus Kirchhof; Dhiraj Gupta
Journal:  Europace       Date:  2014-02-16       Impact factor: 5.214

View more
  1 in total

1.  Chronic Kidney Disease with Mild and Mild to Moderate Reduction in Renal Function and Long-Term Recurrences of Atrial Fibrillation after Pulmonary Vein Cryoballoon Ablation.

Authors:  Giuseppe Boriani; Saverio Iacopino; Giuseppe Arena; Paolo Pieragnoli; Roberto Verlato; Massimiliano Manfrin; Giulio Molon; Giovanni Rovaris; Antonio Curnis; Giovanni Battista Perego; Antonio Dello Russo; Maurizio Landolina; Marco Vitolo; Claudio Tondo
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.